<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626860</url>
  </required_header>
  <id_info>
    <org_study_id>2001P001112</org_study_id>
    <secondary_id>DCMEL-003-00</secondary_id>
    <nct_id>NCT00626860</nct_id>
  </id_info>
  <brief_title>The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma</brief_title>
  <official_title>The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if the vacccine can be used safely in patients with advanced&#xD;
      melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of&#xD;
      producing immune responses against your own cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the toxicity associated with vaccination of melanoma patients with dendritic cell&#xD;
      (DC)/tumor fusions. To determine if cellular and humoral immunity can be induced by serial&#xD;
      vaccination with DC/tumor fusions cells. To determine if vaccination DC/tumor fusions results&#xD;
      in a tumor response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">September 10, 2008</completion_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine</measure>
    <time_frame>screening/baseline, treatment period and follow-up</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC/tumor fusion vaccine</intervention_name>
    <description>SC vaccinations administered to each patient at 3-week intervals for 2-3 doses</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with confirmed diagnoses of disseminated melanoma, with measurable and&#xD;
             clearly progressive metastatic involevment&#xD;
&#xD;
          -  Patients must be at least 18 years old&#xD;
&#xD;
          -  Patients must have ECOG performance status 0-1 with greater than 9 week life&#xD;
             expectancy&#xD;
&#xD;
          -  Those patients with the following accessible tumor will be eligible: soft tissue, bone&#xD;
             marrow or visceral lesions; Skin or superficial soft tissue, or lymph nodes amenable&#xD;
             to resection under local anesthesia; Patients who require surgical procedures that are&#xD;
             not considered significantly invasive but may require general anesthesia, such as&#xD;
             thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be&#xD;
             eligible; Malignant ascites or pleural effusion; Patients requiring major surgical&#xD;
             intervention will be considered ineligible. Patients scheduled to undergo tumor&#xD;
             resection for independent diagnostic or therapeutic indications may have tumor&#xD;
             collected for the purposes of this study.&#xD;
&#xD;
          -  Labs: WBC &gt;_ 2.0 x 10x3/uL, Bilirubin &lt;_2.0 mg/dL, Creatine &lt;_ 2.0mg/dL&#xD;
&#xD;
          -  Women of childbearing age must have a negative pregnancy test and adequate&#xD;
             contraception method(s) must be documented&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and must&#xD;
             give written informed consent in accordance with institutional and federal guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have received other immunotherapy treatment in the past four weeks&#xD;
             prior to study entry&#xD;
&#xD;
          -  Patients must not have received chemotherapy for three weeks prior to the first&#xD;
             vaccination&#xD;
&#xD;
          -  Patients must be without evidence of active CNS disease&#xD;
&#xD;
          -  Patients must not have clinically significant autoimmune disease&#xD;
&#xD;
          -  Patients must be HIV negative&#xD;
&#xD;
          -  Patients must not have serious intercurrent illness such as infection requiring IV&#xD;
             antibiotics, or significant cardiac disease characterized by significant arrhythmia,&#xD;
             ischemic coronary disease or congestive heart failure&#xD;
&#xD;
          -  Patients requiring corticosteroids for either melanoma related or co-morbid illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Avigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIDMC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>David Avigan</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

